Video

Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer (CRC).

Sequencing treatment options for patients with CRC has become complicated, as both physical and molecular factors need to be accounted for, especially with regard to metastatic disease, says Raghav. One of the factors that needs to be taken into consideration is the possibility of surgical resection, Raghav explains.

For example, patients with resectable disease can be approached with curative intent, while patients with unresectable disease will primarily be given palliative therapies, Raghav concludes.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.